Business Wire

SIMPSON-THACHER

13.5.2022 07:02:07 CEST | Business Wire | Press release

Share
Simpson Thacher Adds Prominent Real Estate Finance Partner

Simpson Thacher & Bartlett LLP today announced that James Esterkin will rejoin the Real Estate Practice as a Partner in the Firm’s London office.

James advises private equity sponsors and other investors in connection with the financing of U.K. and European real estate and related assets. He specializes in complex real estate acquisition and development financing, non-performing loan financing arrangements and the restructuring of real estate-related secured debt.

“We are very pleased to welcome James back to our team in London,” said Alden Millard, Chair of Simpson Thacher’s Executive Committee. “James has a unique blend of skills across the real estate sector with experience in all sub-real estate asset classes and European geographies that will be of tremendous value to our clients.”

For nearly 45 years, Simpson Thacher’s London office has advised clients on a wide range of transactions and legal matters throughout Europe. With approximately 185 attorneys, the office offers a team of English and U.S.-trained lawyers advising clients on a broad array of corporate transactions and legal disputes. The Firm’s London Real Estate Practice regularly advises on some of the largest and most complex matters throughout Europe. Recent work includes representing Blackstone Real Estate Partners in connection with nearly all of their financings in the region, across more than 20 jurisdictions and all real estate subsectors, as well as other real estate sponsors, including KKR and Apollo, on almost all of their European sponsor-side real estate finance work. Among its many highlights, the Firm recently advised Blackstone on its €21 billion recapitalization of Mileway—the largest-ever private real estate transaction.

“James will be an excellent addition to our team,” said Tom Lloyd, who leads the Firm’s Real Estate Finance team in the London office. “His extensive experience advising private equity sponsors for almost his entire career will enhance the offerings of our growing real estate finance practice.”

London office Managing Partner Jason Glover noted, “James has established himself as a prominent advisor to an impressive roster of real estate sponsors. He is an exceptional match for our real estate finance capabilities in London.”

“Simpson Thacher is renowned for providing outstanding, innovative advice to the world’s most sophisticated sponsors in the real estate sector,” said James. “I’m thrilled to be returning to the Firm and am excited to further push forward the growth of the Real Estate Finance team in London.”

James was previously a Partner in the London office of Kirkland & Ellis LLP, beginning in 2017. Prior to that, he worked on Simpson Thacher’s London Real Estate team as an Associate from 2013 to 2017. He received his LPC, with distinction, and an LL.M. in International Legal Practice from University of Law, London, and his LL.B. in Law from University of Nottingham. James received a Master of Science in Real Estate Development from University of Westminster.

ABOUT SIMPSON THACHER

Simpson Thacher & Bartlett LLP (www.simpsonthacher.com ) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Brussels, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye